Ranked #3,446 of 8,699 institutional investors
Sanofi
Paris, I0
$550M
US stock portfolio at live prices · today +$7.1M (+1.30%)
Market closed. Prices as of Nov 20, 6:11 AM ET
- Value at quarter end (Q3 2026)
- $630M
- Change from Q2 2026
- +$95.8M (+17.94%)
- Positions
- 15 · 6 new, 0 sold out
- Filed
- Nov 5, 2026
Not counted in the ranking: none$134M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesINBX 15.7%KRSA 12.9%NVAX 9.66%ANAB 7.09%TRAX 6.65%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| INBX Inhibrx Biosciences, Inc. | 1,157,926 | $86.1M | 15.7% | Unchanged |
| KRSA Korsana Biosciences, Inc. | 1,994,011 | $70.7M | 12.9% | New |
| NVAX Novavax, Inc. | 6,880,481 | $53.1M | 9.66% | Unchanged |
| ANAB AnaptysBio, Inc. | 821,917 | $39.0M | 7.09% | Unchanged |
| TRAX First Tracks Biotherapeutics, Inc. | 821,917 | $36.5M | 6.65% | Unchanged |
| ODTX Odyssey Therapeutics, Inc. | 1,990,200 | $36.5M | 6.64% | Unchanged |
| ETRA Electra Therapeutics, Inc. | 2,461,948 | $22.0M | 4.00% | New |
| ATTO Attovia Therapeutics, Inc. | 1,082,855 | $16.9M | 3.07% | New |
| AGMB AgomAb Therapeutics NV | 2,783,096 | $15.6M | 2.85% | Unchanged |
| IMRX Immuneering Corporation | 2,708,559 | $9.3M | 1.70% | Unchanged |
| LTGO Latigo Biotherapeutics, Inc. | 672,778 | $8.9M | 1.62% | New |
| SCTX Scribe Therapeutics Inc. | 500,000 | $6.6M | 1.20% | New |
| SABS SAB Biotherapeutics, Inc. | 2,198,500 | $6.4M | 1.16% | New |
| MPLT MapLight Therapeutics, Inc. | 912,041 | $5.9M | 1.07% | Unchanged |
| QTTB Q32 Bio Inc. | 244,083 | $2.1M | 0.38% | Unchanged |